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Objectives: 
 
To estimate direct medical costs of managing
major macrovascular complications in diabetic patients.
 
Methods:
 
 Costs were estimated for acute myocardial in-
farction (AMI) and ischemic stroke by applying unit costs
to typical resource use profiles. Data were obtained from
many Canadian sources, including the Ontario Case Cost
Project, provincial physician and laboratory fee sched-
ules, provincial formularies, government reports, and
peer-reviewed literature. For each complication, the event
costs per patient are those associated with resource use
specific to the acute episode and any subsequent care oc-
curring in the first year. State costs are the annual costs
per patient of continued management. All costs are ex-
pressed in 1996 Canadian dollars.
 
Results: 
 
Acute hospital care accounts for approximately
half of the first year management costs ($15,125) of
AMI. Given the greater need for postacute care, acute
hospital care has less impact (28%) on event costs for
stroke ($31,076). The state costs for AMI and stroke are
$1544 and $8141 per patient, respectively.
 
Conclusions:
 
 Macrovascular complications of diabetes
potentially represent a substantial burden to Canada’s
health care system. As new therapies emerge that may
reduce the incidence of some diabetic complications,
decision makers will need information to make critical
decisions regarding how to spend limited health care
dollars. Published literature lacks Canadian-specific cost
estimates that may be readily translated into patient-
level cost inputs for an economic model. This paper pro-
vides two key pieces of the many needed to understand
the scope of the economic burden of diabetes and its
complications for Canada.
 
Keywords:
 
 Canada, costs, diabetes, macrovascular com-
plications.
 
Introduction
 
Diabetes mellitus is a clinical condition that rec-
ognizes no geographic or political boundaries. The
International Federation of Diabetes reports that
there were approximately 120 million people with
diabetes worldwide in 1997 and that the prevalence
of diabetes is on the rise globally [1]. In 1990, it
was ranked as one of the top 15 leading causes of
death worldwide with close to 2.8 million diabetes-
related deaths reported. Countries with established
market economies such as Canada, the United States
(US), and the countries of Western Europe contrib-
uted 730,000 deaths to this figure [2]. Self-reported
data from the Canadian Heart Health Survey, con-
ducted between 1986 and 1990, showed that ap-
proximately 5% of the Canadian population, or 1.5
million people, had been diagnosed with diabetes
mellitus. This survey of adults was conducted in 9
of the 10 Canadian provinces and no difference in
prevalence was reported by region [3]. Higher prev-
alence rates of type 2 diabetes have been reported in
the Native Canadian population. One study that
examined a Native Canadian community of 728
persons in Northwest Ontario reported an age-
adjusted prevalence of 26.1%, which is among the
highest in the world [4].
Despite the glycemic control that can be obtained
with diet, oral medications, and/or insulin therapy,
diabetes can have devastating clinical consequences.
In addition to microvascular complications [5,6],
diabetes has also been implicated as the underly-
ing cause of macrovascular complications such as
acute myocardial infarction (AMI), angina pecto-
ris, ischemic stroke, and transient ischemic attacks
[7–9]. Evidence has shown that people with diabe-
tes are two to four times more likely to die from
heart disease or suffer a stroke [10]. Thus, an analy-
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sis of the economic cost of type 2 diabetes must in-
corporate both the immediate cost of treating the
diabetic condition and the downstream costs of
managing the complications inherent in the pro-
gression of the disease.
Clearly, diabetes and its complications must be
an ongoing concern for health care decision mak-
ers in Canada. It has been reported that 21% of
Canadian diabetics have heart disease [11] and
that coronary heart disease is the leading cause of
death in diabetic patients in Canada [3]. Further-
more, the Canadian Diabetes Association (CDA)
has reported that 25% of cardiac surgery can be
attributed to diabetes. These complications also
have major devastating economic consequences,
which must be given careful consideration in to-
day’s health care environment. This is particularly
true for a country such as Canada where a provin-
cially based single payer health care system is oper-
ative. In order to perform accurate economic analy-
ses, it is necessary to have Canadian-relevant costs
that are as recent and complete as possible. Yet,
there are no publications where Canadian resource
use and cost data are used to address macrovascu-
lar complications in diabetic patients at a level de-
tailed enough to be helpful to decision makers.
This paper was written to provide Canadian-
specific cost information for the two most severe
macrovascular complications. Data are presented so
that researchers can examine the costs of each com-
plication on a per-patient basis.
 
Research Design and Methods
 
It should be noted at the outset that this is not a
cost of illness study. These estimates are not for
the total cost of AMIs or strokes among diabetics
in Canada, but rather, the average cost of key com-
ponents of one such episode of illness. No group of
patients was followed through all relevant levels of
care; this could not be done based on available
data. Rather, average per-patient total costs were
estimated by applying unit costs to the likely course
of treatment for each complication. In addition, the
profiles were based on information regarding all in-
dividuals with diabetes and not necessarily those
who were newly diagnosed.
Cost estimates are reported in terms of event
and state costs. Event costs are those associated
with resource use specific to the occurrence of the
defining clinical event. Event cost estimates in-
clude initial inpatient acute care as well as subse-
quent subacute inpatient (e.g., rehabilitation, long-
term care facility), home health, and outpatient care
(e.g., physician visits, medications, day care) ren-
dered in the first year in which the event occurred.
In addition, the acute hospital costs for those re-
admitted in that year for the same event were in-
cluded (Fig. 1). The discharge disposition status
from acute care was used to determine initial sub-
sequent health care use.
Although acute care costs associated with AMI
and ischemic stroke in diabetic patients have been
shown to be substantial [12], the management costs
related to these complications do not cease after the
event or even after the first year because the patient
has entered a new health state, or permanently al-
tered their level of physical condition, due to the
occurrence of the complication. Thus, it is impor-
tant to consider the ongoing, or state, costs.
State costs reflect annual resource use required
beyond the first year for the ongoing management
of the given health state and apply each year while
that particular health state is present for the re-
mainder of the patient’s life. The occurrence of sub-
sequent events, worsening of the condition and other
factors, which may change over time, are not consid-
ered. State costs do not represent a cumulative life-
time cost. The state cost of a complication presented
in this paper refers to the one-year management cost
for any year subsequent to the event year. All event
and state costs that are reported for each complica-
tion are incremental to any recommended screen-
ing, prevention measure, or diabetes treatment that
take place as part of diabetes management, the
costs of which are not included in this analysis.
Developing a cost estimate for a clinical condi-
tion is not unlike creating a patchwork quilt. Be-
cause there is no one perfect data source from which
all relevant resource use and cost information can
be abstracted, it is necessary to gather cost-related
Figure 1 Cost estimate components.
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pieces of information from a variety of sources. De-
termining which sources to use is always a balanc-
ing act between relevance, credibility, and availabil-
ity. To provide cost estimates for these complications,
it was necessary to obtain pertinent information from
many different sources. Acute inpatient care resource
use and costs were derived primarily from 1994/95
data from the Ontario Case Cost Project (OCCP)
[13]. Patients were identified by means of Interna-
tional Classification of Diseases (ICD-9) codes [14].
Diabetic patients primarily admitted for AMI were
identified by a principal diagnosis using ICD-9 codes
410.0–410.9 and any secondary diagnosis code
documenting diabetes (ICD-9: 250.00–250.93). The
same methodology was used to identify those admit-
ted for ischemic stroke, substituting stroke-related
codes (ICD-9: 433.x1; 434.xx, 436) for the princi-
pal diagnosis. This process yielded a population of
465 diabetic patients with AMI and 1593 with
ischemic stroke, respectively.
Acute care hospital cost estimates include all ac-
commodation, ancillary services (e.g., pharmacy,
laboratory), operating room, diagnostic and thera-
peutic procedures, and physician costs. Since phy-
sician costs are not included in the discharge data
and are not reported in the literature in sufficient
detail by complication, it is necessary to develop an
inpatient physician resource use profile for each com-
plication. Physician-related costs were developed
by creating a complication-specific profile primarily
based on length of stay (LOS), physician service
data, Case Mix Group (CMG) and severity level
assignment based on the OCCP data. To this base-
line cost, fees were added proportionally to the
utilization of the service to account for the differ-
ential use of more resource-intensive services for
each complication, such as emergency room use,
surgical procedures, special care unit stays and con-
sultations. To develop the complete health care re-
source use profile and cost estimates for these com-
plications beyond acute hospital care, these data
were supplemented with information from many
sources including the Canadian Diabetes Associa-
tion [9], Heart Disease and Stroke Foundation of
Canada [15], Health Canada [16,17], clinical guide-
lines [18], other government reports [19,20], and
peer-reviewed literature [21–39]. References to both
type 1 and type 2 diabetes were considered for esti-
mating the management costs of a complication.
Unit cost information for physician-related care,
laboratory tests, and medications came from the
many provincial fee schedules and formularies across
Canada. It was necessary to conduct telephone sur-
veys of various providers in a number of provinces
to obtain unit cost data for the following cost cen-
ters: day care, cardiac rehabilitation programs, and
ambulance services, since no published unit cost
data were available for these health care services.
The majority of unit cost and resource use data
applied in this analysis were developed from Ca-
nadian sources; however, due to the lack of avail-
able Canadian-specific detailed data for some post-
acute care, it was necessary to use US-based resource
use data in rare cases. For example, OCCP data are
dichotomized into alive or dead discharge catego-
ries; therefore, it was not possible to obtain Cana-
dian-specific disposition status by subsequent site of
care for AMI from either these data or the medical
literature. Thus, it was necessary to employ diag-
nosis-specific disposition status data for a similar
population from five 1994/95 [40–44] US all-payer
state databases to derive initial postacute care pat-
terns. The proportions were adjusted to reflect the
difference in the Canadian versus US case fatality
rates (CFR) for diabetics with AMI.
Given the increased postacute care requirements
of stroke compared to AMI, our previously devel-
oped stroke economic model was employed to derive
the state costs [45]. These subsequent costs were es-
timated by modeling the course of survivors of the
initial event. For disabling strokes, the initial dis-
position status post discharge was based on Cana-
dian disposition data, which were incorporated into
the model. Because Canadian-specific data regard-
ing transitions to other levels of care over time were
not available, the aforementioned model that ex-
amines transitions over a 12-year period was em-
ployed. The long-term transition data used in this
model comes from work done by Thorngren and
Westing in Sweden [46]. The model was adapted
to reflect Canadian-specific cost data.
Because the Canadian health care system is based
on provincial, rather than national, decision making
and each province sets its own level of reimburse-
ment, we gathered data from all provinces whenever
possible to create a national average (e.g., physician
costs, medications, laboratory tests); however, for
some cost centers (e.g., inpatient acute hospital care),
data from only one province were available. In such
cases, whenever possible, we calculated the national
cost of that care by using a ratio of that provincial
cost to a published Canadian average cost to cre-
ate a national unit cost for that cost center. For ex-
ample, the inpatient costs were based on data from
Ontario only. Based on data from Statistics Canada
[47], we were able to establish that hospital costs in
Ontario were 20.4% higher than the Canadian av-
erage. The cost of acute hospital care reported in
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this paper reflects the adjustment made to report a
Canadian average cost.
The majority of the unit cost data in this analy-
sis was taken from sources reporting 1996 Cana-
dian dollar values; therefore all event and state
cost estimates are reported as costs in 1996 Cana-
dian dollars. Where 1996 values were not available,
older estimates were inflated or later values deflated
using the Medical Care Inflation Index (a compo-
nent of the Consumer Price Index) supplied by
Statistics Canada.
 
Results
 
The mean event and state costs for AMI and is-
chemic stroke are presented in Table 1.
 
Acute Myocardial Infarction
 
The mean event cost for AMI was estimated to be
$15,125 (range: $7,613–$84,310). On average, costs
related to acute hospitalization (mean: $7514; range:
$924–$76,697) for the initial event, including the
cost of preadmission ambulance/CPR care, comprised
almost half (49.6%) of first-year management costs.
The mean LOS in acute care for diabetic patients ad-
mitted primarily for AMI was 9.8 days (range: 1–66
days) and the CFR was 17% during the hospital stay.
This CFR reflects an additional 5.3% compared to
AMI cases without documented diabetes. On average,
those with diabetes remained in the hospital almost 1
day (0.8) longer for the AMI-related admission.
In addition to the acute hospitalization, event
costs for AMI include all first-year subsequent care
costs described previously (Fig. 1) plus cardiac reha-
bilitation programs and cardiac related medications
(i.e.,  blockers, aspirin, ACEIs, nitrates, and choles-
terol lowering agents).
AMI can be managed conservatively with just
medications or with a more aggressive approach,
such as angioplasty or surgical revascularization.
While the costs related to coronary angiography,
coronary artery bypass grafts (CABG), and percuta-
neous transluminal coronary angioplasty (PTCA)
are included in the acute care costs for those dia-
betic patients who had these procedures during their
initial hospitalization, some patients accrue these
costs after discharge. The cost of these procedures
for the proportion of diabetic patients receiving
them in the year subsequent to their initial hospi-
tal stay (30.4% angiography, 10.3% angioplasty,
and 5.6% bypass surgery) was also included in the
event cost. These figures were derived from previ-
ously published Canadian studies [29,31,33,37].
In addition, 7% of diabetics experiencing an
AMI were readmitted within the first year for a sec-
ond AMI. The cost of this hospitalization and sub-
sequent postacute care has been factored into the
event cost estimate.
State costs of AMI were calculated to be $1544
(range: $558-$4071) per patient per year on aver-
age. These included the cost of medications, physi-
cian visits, and monitoring cardiology tests (i.e.,
ECG and stress test). A small proportion of diabetic
patients who experienced an AMI (1.4%) require
permanent long-term care facility placement. The
cost of this care is also reflected in the state cost.
 
Ischemic Stroke
 
The disabling consequences of stroke have a more
profound effect on first year management costs. This
is evident in the proportional decrease of effect that
acute hospital costs exhibit on the event costs for
stroke when compared to AMI (Fig. 2). The mean
acute care hospital costs for ischemic stroke were es-
timated to be $8591 (range: $610–$187,491). The
mean hospital cost estimate comprises 28% of the
average total event cost of $31,076 (range: $23,094–
$209,976). This is understandable when one exam-
ines the need for care services at the postacute level
required by stroke patients.
 
Table 1
 
Mean cost of major macrovascular complications
(1996 $Canadian)
 
Diabetic complication Event cost State cost
Acute myocardial infarction $15,125 $1,544
Ischemic stroke $31,076 $8,141
Figure 2 Proportion of initial hospital costs to event costs,
by complication. Subsequent care includes rehabilitation, home
health care, long-term care, outpatient care, medications and
readmission within first year for same condition.
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OCCP data report both the total LOS and the
number of days attributable to acute care during a
hospital stay. For AMI management, virtually all
of the hospital stay is comprised of time in acute
care; however, this is not the case with stroke
patients. The mean acute care LOS for ischemic
stroke is 14.4 days (range: 1–292), whereas the
mean total LOS is 21.8 days (range: 1–579). Thus,
on average, only 66% of the total hospital LOS
was attributed to acute care for stroke patients.
Although OCCP data do not specify hospital site
of care by day, we deduced that this additional
time was spent in either a rehabilitation unit or a
long-term care ward based on information derived
from the literature [23,24,30].
Unlike AMI, published data on site-specific dis-
position status of Canadian stroke patients at the
time of discharge were available [30]. Upon dis-
charge from acute care, approximately 30% of pa-
tients suffering ischemic stroke were referred to re-
habilitative or subacute inpatient care and another
14% received home health care. Of those dis-
charged alive, 4.1% were readmitted for another
stroke event within the year. The mean annual state
cost for managing a patient with ischemic stroke
was estimated to be $8141 (range: $2320–$20,139).
 
Discussion
 
While many complications attributable to diabetes
give rise to concern, particular notice is being paid
to major macrovascular problems. There are sound
clinical and economic reasons for this attention.
The chief cause of morbidity and mortality in dia-
betic patients is macrovascular disease, particu-
larly coronary artery disease (CAD). Diabetes has
been reported to be the major underlying cause of
AMI in persons under 40 years of age and it has
been estimated that more than half of patients
with type 2 diabetes already have CAD when di-
agnosed with diabetes [8]. Between 75% and 80%
of adults suffering from diabetes will die from ath-
erosclerotic disease [20].
When the US direct medical costs of complica-
tions related to type 2 diabetes were published in
1998 [12] it was surprising, given the scope of the
disease, that there were no recent papers providing
comprehensive patient-level cost estimates for the
majority of relevant diabetic complications. This
is also the case for Canada, where very little diag-
nosis-specific resource use and cost data for diabetes
are published or available. Although an extensive
literature search was performed and some cost-
related information for diabetes is reported [48],
no papers detailing resource use or cost informa-
tion for these macrovascular complications were
found to compare with the findings of this study.
It is not uncommon to find proxy cost estimates
for diabetes in Canada based on US or European
estimates, even in Canadian reports [9]. Citing the
relative size of the population in Canada com-
pared with that of the US, a published projection
of the 9 billion dollars spent annually in Canada
on diabetes-related direct and indirect costs is
based on 10% of the US annual costs [19]. Al-
though this figure may not be a precise estimate of
the annual cost, clearly it is impressive and helps
alert those who need to be concerned with health
care budgets that this is a clinical condition that
requires attention. However, is it meaningful to
those who need to develop economic models to as-
sist decision makers concerning new therapeutic
interventions for diabetes? Those performing pa-
tient-level economic analyses require information
at a more detailed level. The objective of this pa-
per is to provide such cost information.
The importance of country-specific resource use
and unit cost data cannot be ignored. The Cana-
dian-specific cost estimates presented in this paper
are based, with rare exception, on data from Ca-
nadian sources. In the early stages of this analysis,
a model based on US data was used, adjusting unit
cost and resource use data to fit a Canadian pro-
file as data became available. Some of the prelimi-
nary estimates relied heavily on US resource use
profiles and a mixture of Canadian unit costs and
US costs converted to Canadian dollars. Once the
model was updated to reflect actual Canadian re-
source utilization and all Canadian costs, it be-
came evident that proxy data from the US should
not be used unless there was absolutely no alterna-
tive. The original state cost estimate for stroke us-
ing the US/Canadian mixture was $6750. Com-
pared with the current state cost estimate for stroke
($8141) presented in this paper, it is clear that an un-
derestimate of the cost of managing stroke in Can-
ada would have been made for each patient for each
year the patient was in that health state if the proxy
US data had been employed.
This difference in estimates using proxy versus
country-specific data is not surprising since cost
estimates do not translate directly from country to
country. Health care systems, available services,
and medical practice patterns affect the cost of care.
While there may be agreement on a clinical level as
to the management of an illness, actual delivery of
care may differ.
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The following examples illustrate this point.
OCCP data show a mean total LOS of almost 22
days for a patient admitted for stroke with only
14.4 days attributable to an acute level of care.
For similar patients from the same time period in
the US, the average hospital LOS was 8.8 days
[40–44]. Although there are some designated re-
habilitation and skilled nursing level beds in some
hospitals in the US, for the most part the care re-
ceived in hospitals is at an acute level. The usual
practice pattern in the US is to discharge patients
to less costly facilities for postacute care as war-
ranted. This does not seem to be the case in Can-
ada; more rehabilitative care is done within the
acute care facility and delays in discharge have
been reported due to a lack of available skilled nurs-
ing or long-term care facility beds in the community
[20,30]. Even when just the acute care portion of
the hospital stay is compared, a substantial differ-
ence is seen between the two countries.
Another example addresses the difference in rates
of surgical procedures. When the rate of CABG pro-
cedures for diabetic patients admitted for AMI in
the US was examined, 8% had this surgery during
their initial stay [40–44]. This figure drops dramati-
cally for similar patients treated in Canada in the
same time period. Based on OCCP data, the rate
in Canada was 4%. Pilote et al. revealed similar
proportional differences in a study comparing pa-
tients treated in the US versus those treated in
Canada [31]. OCCP data available for this analy-
sis did not allow segregation of incremental costs
of CABG for these patients; however, based on a
previous analysis using US data, it is clear that
surgical revascularization adds a considerable in-
cremental cost to the stay of an AMI patient. Us-
ing 1995 Massachusetts data [44], those diabetic
patients who had CABG during their admission
for AMI accrued 3.4 times the cost of those who
did not. Although this increment may not be the
same in Canada, it does point out that rates of pro-
cedures and other health care services can make a
difference in the cost of managing a given illness.
Given this, the limited use of US-based resource
use data in this analysis of AMI may not provide a
precise estimate for Canada. Nevertheless, it is
as accurate an estimate as possible based on the
available data. To our knowledge, this paper pro-
vides Canadian-specific cost estimates for two ma-
jor complications of diabetes at a level not previ-
ously published. However, if these costs are used
in health economic models for the purpose of cal-
culating costs over time, appropriate discounting
should be employed.
When using administrative databases, the issue
of coding accuracy arises. As populations are se-
lected based on the presence of a given ICD-9 code,
there is a possibility of error in the coding process.
There is conflicting information in the literature re-
garding the accuracy of coding diabetes. One re-
port from Scotland published in 1992 notes that
60% of patients with known diabetes had no such
code on their record [49]; however, more recent
evidence that coding of complications in diabetic
patients is very accurate has been published. In a
population of diabetic patients in the state of Wash-
ington, AMI and stroke were coded accurately in
95.2% and 91.2% of cases, respectively [50]. Given
the increased reliance on administrative databases
in recent years for reimbursement and research, it
is likely that the error rate is indeed decreasing. No
information is available regarding the coding error
rate in the OCCP data, but for purposes of this anal-
ysis, it is only a problem if there is a cost-relevant
bias in the patients included. Whether such a bias ex-
ists is unclear.
The task of developing representative cost esti-
mates for any illness is akin to creating a jigsaw puz-
zle. If pieces are missing or they are not put together
in the right manner, the end result may not be a
complete or accurate picture. Ideally, cost estimates
would be developed from a comprehensive study of
unselected patients with sufficient follow-up, but
also a design that does not influence resource use. In
the absence of ideal data, one must use information
from a variety of sources. This may introduce some
error, since there is no assurance that these sources
are coherent. Nevertheless, such estimates provide
essential information for decision makers who can-
not wait until the ideal data accumulate.
The cost estimates provided in this paper are
just two of the many pieces needed to complete a
cost picture of the economic burden of diabetes
and its complications for Canada. We believe, how-
ever, that they are key pieces and will not only help
broaden awareness of the economic consequences of
this chronic disease, but will also provide estimates
that can be used in disease models that inform health
care decision makers.
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